Dispensation of long-acting β agonists with or without inhaled corticosteroids, and risk of asthmarelated hospitalisation: A population-based study

Thorax

Volumn 69, Issue 4, 2014, Pages 328-334

  Sadatsafavi, Mohsen ^a,b   Lynd, Larry D ^a   Marra, Carlo A ^a   FitzGerald, J Mark ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Research Pavilion   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; LONG ACTING DRUG; SHORT ACTING DRUG;

ADULT; ARTICLE; ASTHMA; CANADA; CASE CONTROL STUDY; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EXPOSURE; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; INHALER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION;

ASTHMA;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BRITISH COLUMBIA; CASE-CONTROL STUDIES; CHILD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84895923268     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2013-203998     Document Type: Article

References (34)

1. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010;362:1169-71.
2. Kramer JM. Balancing the benefits and risks of inhaled long-acting beta-agonists-The influence of values. N Engl J Med 2009;360:1592-5.
3. Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N Engl J Med 2011;364:2473-5.
4. Rodrigo GJ, Castro-Rodríguez JA. Safety of long-acting {beta} agonists for the treatment of asthma: clearing the air. Thorax 2012;67:342-9.
5. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992;327:1420-5.
6. Wenzel SE, Lumry W, Manning M, et al. Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma. Ann Allergy Asthma Immunol 1998;80:463-70. (Pubitemid 28285669)
7. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000;320:1368-73. (Pubitemid 30261116)
8. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219-24. (Pubitemid 24229008)
9. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004;170:836-44. (Pubitemid 39346477)
10. Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006;144:904-12. (Pubitemid 46768131)
11. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26. (Pubitemid 43265239)
12. Levenson M. Long-acting beta-agonists and adverse asthma events meta-analysis. United States Food and Drug Administration, 2008.
13. Suissa S, Ariel A. US Food and Drug Administration-mandated trials of long-acting β-agonists safety in asthma: will we know the answer? Chest 2013;143:1208-13.
14. BC Ministry of Health. Population Data BC. http://www.popdata.bc.ca/data (accessed 20 Nov 2011).
15. Ministry of Health. PharmaNet. http://www.health.gov.bc.ca/pharmacare/ pharmanet/netindex.html (accessed 29 Mar 2012).
16. Williams J, Adger W. Inventory of studies on the accuracy of Canadian health administrative databases. Toronto: Institute for Clinical Evaluative Sciences, 1996.
17. Canadian Institute for Health Information. CIHI Data Quality Study of the 2005-2006 Discharge Abstract Database. Ottawa, Ontario, 2009. https://secure.cihi.ca/free-products/DAD-DQ-study-2005-2006-August-2009-e.pdf (accessed 8 Sep 2012).
18. Hu W. Diagnostic Codes in MSP Claim Data, Summary Report. Victoria: Medical Services Plan, 1996.
19. Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011;305:2525-31.
20. Schneeweiss S, Walker AM, Glynn RJ, et al. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med 2002;346:822-9. (Pubitemid 34984656)
21. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;308:247-56.
22. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 2002;57:880-4. (Pubitemid 35178613)
23. Mantel N. Synthetic retrospective studies and related topics. Biometrics 1973;29:479-86.
24. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6.
25. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343:332-6. (Pubitemid 30616699)
26. Schlesselman JJ, Stolley PD. Case-control studies: design, conduct, analysis. Oxford University Press, 1982.
27. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9. (Pubitemid 41587600)
28. Hudson M, Suissa S. Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010;62:805-10.
29. Wang M-T, Skrepnek GH, Armstrong E, et al. Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma. Curr Med Res Opin 2008;24:859-67. (Pubitemid 351428997)
30. Wells KE, Peterson EL, Ahmedani BK, et al. The relationship between combination inhaled corticosteroid and long-acting β-agonist use and severe asthma exacerbations in a diverse population. J Allergy Clin Immunol 2012;129: 1274-9.e2.
31. Postmarket Drug Safety Information for Patients and Providers. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm213836.htm (accessed 3 Apr 2012).
32. Brozek JL, Kraft M, Krishnan JA, et al. Long-acting β2-agonist step-off in patients with controlled asthma: systematic review with meta-analysis. Arch Intern Med 2012;1-11. doi:10.1001/archinternmed.2012.3250
33. Gappa M, Zachgo W, von Berg A, et al. Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED). Pediatr Pulmonol 2009;44:1132-42.
34. Delea TE, Hagiwara M, Stanford RH, et al. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma. Clinical Therapeutics 2008;30:560-71. (Pubitemid 351483930)